NEW YORK, NY -- (Marketwired) -- 10/02/13 -- Plandaí Biotechnology Inc. (OTCQB: PLPL) already has a technology in place that is allowing it to boast of higher bioavailability with its Phytofare" products than other nutraceutical producers in the industry; however, the company isn't stopping there and has entered into an exclusive license agreement that allows it the use of Pheroid" technology -- a deal that makes its products even stronger than first reported.
Plandaí continues in its pursuit to bring products to the marketplace that can benefit its users with much higher absorption rates, and to that end, the addition of the Pheroid technology should dramatically enhance its products.
The Pheroid technology is an encapsulation or entrapment technology that encases the target material inside of a long-chain fatty acid. Plandaí obviously jumped at the opportunity to add this technology to its work with botanicals because it will serve two purposes en route to improving bioavailability.
First, the target cells perceive the fatty acid as food and allow the Pheroid to pass through the cell membrane which greatly enhances bioavailability, or absorption. Second, the fatty acid protects the entrapped material from damage as it passes through the gastro-intestinal tract.
The benefit to Plandaí and its customers is that by using the Pheroid technology, it will allow the company to get its Phytofare" molecules to the target tissues undamaged which, in turn, promotes greater efficacy. Our bodies digest all that we consume, and in that process the phytochemical molecules, in this case, Phytofare, are broken down into metabolites.
Without the use of the Pheroid technology, this could prove problematic because often the parent, or intact, molecule will have different properties than the metabolites. In the case of green tea catechins, the un-metabolized molecules have vastly different benefits, and therefore, the Pheroid technology will help Plandaí deliver its highly bioavailable products intact and fully functional directly to the target tissues.
Biotech investors should get excited about this new technology as Plandaí now owns the license for entrapping all plant molecules opening the door for the company to develop products using their full lineup of botanicals. This includes catechins (green tea), limonoids and glycosides (citrus), carotenoids (tomato, gac, berries), and eventually other botanical extracts in development.
It is the addition of the Pheroid technology that could potentially allow Plandaí to use these natural products to treat many different diseases and conditions such as diabetes, cancers, erectile dysfunction, obesity, Alzheimer's, MS, and AIDS.
While botanical products have proven efficient in treating all of these in the laboratory, it has been the lack of bioavailability and an efficient delivery system that has impeded efforts to develop functional drugs. Plandaí and the Pheroid technology could change all of that.
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, CEO Interviews and Feature Articles. For more information: www.stockmarketmediagroup.com
Contact: Stock Market Media Email Contact
Source: Plandai Biotechnology, Inc. (PLPL.OB)